Spritam Patent Expiration

Spritam is a drug owned by Aprecia Pharmaceuticals Llc. It is protected by 5 US drug patents filed from 2015 to 2021. Out of these, 3 drug patents are active and 2 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 14, 2034. Details of Spritam's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9339489 Rapid disperse dosage form containing levetiracetam
Mar, 2034

(9 years from now)

Active
US9669009 Rapid disperse dosage form containing levetiracetam
Mar, 2034

(9 years from now)

Active
US11160786 Rapid disperse dosage form
Mar, 2034

(9 years from now)

Active
US6471992 Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
Feb, 2018

(6 years ago)

Expired
US9463160 Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
Feb, 2018

(6 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Spritam's patents.

Given below is the list of recent legal activities going on the following patents of Spritam.

Activity Date Patent Number
Patent litigations
Post Issue Communication - Certificate of Correction 26 Jan, 2022 US11160786
Patent Issue Date Used in PTA Calculation 02 Nov, 2021 US11160786
Recordation of Patent Grant Mailed 02 Nov, 2021 US11160786
Email Notification 14 Oct, 2021 US11160786
Issue Notification Mailed 13 Oct, 2021 US11160786
Application Is Considered Ready for Issue 01 Oct, 2021 US11160786
Dispatch to FDC 01 Oct, 2021 US11160786
Issue Fee Payment Verified 28 Sep, 2021 US11160786
Issue Fee Payment Received 28 Sep, 2021 US11160786
Email Notification 01 Sep, 2021 US11160786

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Spritam is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Spritam's family patents as well as insights into ongoing legal events on those patents.

Spritam's Family Patents

Spritam has patent protection in a total of 9 countries. It's US patent count contributes only to 34.8% of its total global patent coverage. Click below to unlock the full patent family tree for Spritam.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Spritam's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 14, 2034 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Spritam Generic API suppliers:

Levetiracetam is the generic name for the brand Spritam. 75 different companies have already filed for the generic of Spritam, with Prinston Inc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Spritam's generic

Alternative Brands for Spritam

Spritam which is used for treating seizures or epilepsy., has several other brand drugs using the same active ingredient (Levetiracetam). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Tripoint
Elepsia Xr
Ucb Inc
Keppra
Keppra Xr


Apart from brand drugs containing the same ingredient, some generics have also been filed for Levetiracetam, Spritam's active ingredient. Check the complete list of approved generic manufacturers for Spritam





About Spritam

Spritam is a drug owned by Aprecia Pharmaceuticals Llc. It is used for treating seizures or epilepsy. Spritam uses Levetiracetam as an active ingredient. Spritam was launched by Aprecia Pharms in 2015.

Approval Date:

Spritam was approved by FDA for market use on 31 July, 2015.

Active Ingredient:

Spritam uses Levetiracetam as the active ingredient. Check out other Drugs and Companies using Levetiracetam ingredient

Treatment:

Spritam is used for treating seizures or epilepsy.

Dosage:

Spritam is available in tablet, for suspension form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
1GM TABLET, FOR SUSPENSION Prescription ORAL
750MG TABLET, FOR SUSPENSION Prescription ORAL
250MG TABLET, FOR SUSPENSION Prescription ORAL
500MG TABLET, FOR SUSPENSION Prescription ORAL